Thomas Hofmann, MD, PhD

Dr. Thomas Hofmann has spent more than 25 years as a clinical developer of inhaled therapies for lung diseases and is an international leader in the study and treatment of pulmonary diseases such as Cystic Fibrosis, Asthma, COPD and Bronchiectasis. Most recently he served as Chief Scientific Officer of MannKind Corporation, following the acquisition of Qrumpharma, a pharmaceutical company he founded. Previously, Dr Hofmann held multiple executive positions in the pharmaceutical industry, including at Aumapharma LLC, Activaero GmbH, Discovery Labs, Corus Pharma, and Pulmopharm. Earlier he served as an adjunct professor of biomedical engineering at Temple University. He is the holder of numerous patents related to pulmonary diseases therapies and widely published in medical journals on the subject of treatment of lung diseases, and is a recipient of the Milton Graub Clinical Achievement Award from the U.S. Cystic Fibrosis Foundation. He earned his MD and PhD at Justus Liebig University Giessen in Germany and completed postdoctoral research in cystic fibrosis at University of North Carolina School of Medicine.